PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19.
Chakraborty, Arup R
Taylor, Louis J
McGrath, Marisa E
Furlong, Brooke A
Carlson, Kenneth E
Ingber, Donald E
DePamphilis, Melvin L
Frieman, Matthew B
MetadataShow full item record
AbstractThe ongoing COVID-19 pandemic has claimed more than 6 million lives and continues to test the world economy and healthcare systems. To combat this pandemic, the biological research community has shifted efforts to the development of medical countermeasures, including vaccines and therapeutics. However, to date, the only small molecules approved for the treatment of COVID-19 in the United States are the nucleoside analogue Remdesivir and the protease inhibitor Paxlovid, though multiple compounds have received Emergency Use Authorization and many more are currently being tested in human efficacy trials. One such compound, Apilimod, is being considered as a COVID-19 therapeutic in a Phase II efficacy trial. However, at the time of writing, there are no published efficacy data in human trials or animal COVID-19 models. Here we show that, while Apilimod and other PIKfyve inhibitors have potent antiviral activity in various cell lines against multiple human coronaviruses, these compounds worsen disease in a COVID-19 murine model when given prophylactically or therapeutically.
Data AvailibilitySingle-cell sequencing data (raw reads) have been deposited in the NCBI Sequence Read Archive under accession number PRJNA841980.
Rights/Terms© 2022. The Author(s).
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19597
- The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
- Authors: Baranov MV, Bianchi F, van den Bogaart G
- Issue date: 2020 Dec 27
- Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
- Authors: Kreutzberger AJB, Sanyal A, Ojha R, Pyle JD, Vapalahti O, Balistreri G, Kirchhausen T
- Issue date: 2021 Oct 13
- Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
- Authors: Artese A, Svicher V, Costa G, Salpini R, Di Maio VC, Alkhatib M, Ambrosio FA, Santoro MM, Assaraf YG, Alcaro S, Ceccherini-Silberstein F
- Issue date: 2020 Dec
- Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.
- Authors: Stone NE, Jaramillo SA, Jones AN, Vazquez AJ, Martz M, Versluis LM, Raniere MO, Nunnally HE, Zarn KE, Nottingham R, Ng KR, Sahl JW, Wagner DM, Knudsen S, Settles EW, Keim P, French CT
- Issue date: 2021 Jan 19
- A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
- Authors: Khazir J, Maqbool T, Mir BA
- Issue date: 2021